Courses

Applying S1P Therapeutics to Improve Outcomes for Patients with Moderate to Severe Ulcerative Colitis

Applying S1P Therapeutics to Improve Outcomes for Patients with Moderate to Severe Ulcerative Colitis

This CME activity is derived from content presented at the Digestive Disease Week (DDW) 2021 Virtual Meeting. The expert faculty will highlight sphingosine-1-phosphate (S1P) therapeutics to improve outcomes for patients with moderate to severe ulcerative colitis (UC). Additionally, a review of S1P receptor modulators as a therapeutic target to support the management of ulcerative colitis will be discussed. The faculty ...
View Course
Applying New Science to Patient-Focused Treatment Strategies Across the Spectrum of Multiple Sclerosis

Applying New Science to Patient-Focused Treatment Strategies Across the Spectrum of Multiple Sclerosis

This CME/CE activity is derived from content presented at the 6th Annual Advanced Curriculum for Multiple Sclerosis 2021 Virtual CME/CE Course. The expert faculty, led by Dr. Fred D. Lublin, will first review the science of the evolving spectrum of multiple sclerosis (MS) to better understand the course of MS disease activity, as well as optimal treatment solutions to reduce ...
View Course
Applying New Science to Symptom Management Across the Spectrum of Multiple Sclerosis

Applying New Science to Symptom Management Across the Spectrum of Multiple Sclerosis

This CME/CE activity is derived from content presented at the 6th Annual Advanced Curriculum for Multiple Sclerosis 2021 Virtual CME/CE Course. The expert faculty, led by Dr. Fred D. Lublin, will first provide an overview of comorbidities in multiple sclerosis (MS), as well as primary, secondary and tertiary symptoms. Cannabis/cannabinoid use in MS will be reviewed and efficacy on spasticity ...
View Course
A Scientific Analysis: The Long-Term Role for S1P Receptor (1,5) Modulator Therapeutics for the Effective Management of Patients with Relapsing MS

A Scientific Analysis: The Long-Term Role for S1P Receptor (1,5) Modulator Therapeutics for the Effective Management of Patients with Relapsing MS

This CME/CE activity is derived from content presented at the 6th Annual Advanced Curriculum for Multiple Sclerosis 2021 Virtual CME/CE Course. The expert faculty, led by Dr. Fred D. Lublin, will first outline the science, mode of action, and unmet needs for S1P modulator therapies for patients with relapsing multiple sclerosis, including immune factors and strategies for initiating treatment among ...
View Course
The New and Emerging Role of Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapeutics to Improve Long-Term Outcomes in Patients with Relapsing Multiple Sclerosis

The New and Emerging Role of Bruton’s Tyrosine Kinase Inhibitor (BTKi) Therapeutics to Improve Long-Term Outcomes in Patients with Relapsing Multiple Sclerosis

This CME/CE activity is derived from content presented at the 6th Annual Advanced Curriculum for Multiple Sclerosis 2021 Virtual CME/CE Course. The expert faculty, led by Dr. Fred D. Lublin, will review the science and mode of action for Bruton's Tyrosine Kinase (BTK) inhibitors. The faculty will analyze the role of BTK in microglia and the clinical trial data on ...
View Course
Advanced Therapeutics in Movement Disorders

Advanced Therapeutics in Movement Disorders

This CME program will highlight recent advances in the treatment and management of patients with Parkinson’s disease (PD), covering topics such as OFF episodes, deep brain stimulation (DBS) and psychosis. The expert faculty, led by Dr. Stuart Isaacson, will first delve into OFF episodes, analyzing the causes of OFF periods, and the impact on quality of life and patient perceptions, ...
View Course
Addressing Healthcare Disparities and COVID-19 Concerns for All Patients with Multiple Sclerosis

Addressing Healthcare Disparities and COVID-19 Concerns for All Patients with Multiple Sclerosis

This CME/CE symposium, led by Fred D. Lublin, MD, is derived from content presented at the Virtual ACTRIMS Forum in February, 2021. In this program, the expert faculty will review current disparities for the management of patients across the entire spectrum of disease with multiple sclerosis (MS). The faculty will discuss the immune-science relationship between COVID-19 infections and therapeutic options ...
View Course
Novel Targeted Therapies to Slow Disease Progression in Patients with Early-Stage Alzheimer’s Disease

Novel Targeted Therapies to Slow Disease Progression in Patients with Early-Stage Alzheimer’s Disease

This CE activity will highlight novel therapies to slow disease progression in patients with early-stage Alzheimer’s disease (AD), including data presented at the Virtual 13th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Digital Conference 2020. The expert faculty, led by Dr. Richard S. Isaacson, will first delve into the pathophysiology, early and accurate differential diagnosis and disease course of Alzheimer’s ...
View Course
Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

Anti-Programmed Cell Death (PD) Therapies for the Management of Patients with Lung Cancer

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and M. Patricia Rivera, will first provide a review of current science in non-small cell lung cancer (NSCLC), including trends in stage distribution of lung cancer. Following, current data for targeted therapies as well as immunotherapies in various ...
View Course